Detailed Narrative
Q1 FY27 Strong Financial Performance
Thyrocare reported a robust start to FY27, with standalone revenue growing 26.1% year-on-year to INR225.6 crores and consolidated revenue increasing 24.3% to INR240 crores. The pathology business, excluding COVID, demonstrated strong growth of 26% in Q1 FY27. This performance translated into a 32.2% EBITDA margin, up 34% YoY, and a PAT of INR51.3 crores, also a 34% YoY increase, reflecting disciplined execution and focus on profitable growth.
Strategic Expansion into Specialty Diagnostics
The company is strategically extending its focus into specialty diagnostics, aiming to address the underpenetrated market with limited accessibility and premium pricing. Management's ambition is for specialty forms to contribute 15-20% of the total portfolio within a three to five-year timeline. Initial investments in central processing labs in Mumbai and Delhi for specialty tests are largely complete, with future capex primarily linked to volume growth.
Network Growth and Operational Excellence
Thyrocare's active franchisee network has grown significantly to over 11,700, a fourfold increase since July 2021. The laboratory network has also expanded from 17 labs in FY21 to 44 labs today, ensuring broader geographic reach. The company continues to invest in technology and automation, maintaining a home collection network of 2,000 phlebotomists with a 99% on-time arrival rate, and all its laboratories are NABL affiliated.
Enhanced Patient Experience and Quality Focus
A core focus remains on improving patient experience and quality, with complaint management achieving Six Sigma levels at 3.1 complaints per million tests. The turnaround time for reports has been reduced to 3.37 hours. The company also clarified its test reporting methodology, now excluding calculated parameters not billed to patients, to provide a more accurate representation of actual processed tests.
Parent Company Debt Reduction and Strategic Outlook
API Holding, the parent company, has reduced its debt from INR1,700 crores to INR1,050 crores. Management indicated that an IPO or reverse merger for API Holding is not planned for at least 12 months, as the current focus is on making other API businesses profitable and debt-free. This approach aims to ensure a stronger foundation before considering major corporate actions.
Divestment of Radiology Business
Thyrocare has announced its intent to divest the radiology business, acknowledging its dilutive impact on consolidated return ratios. The divestment process is anticipated to take approximately six months, with Q1 FY27 PAT for the radiology segment reported at INR1.72 crores, and an expected INR6 crores for the full FY27. This move aligns with the strategy to focus on core profitable growth areas.
Consumables Business Strategy Under Review
The company is actively working on a strategy for Thyrocare-branded consumables, distinct from backward integration. An announcement regarding this new initiative is expected by September. This indicates a potential new avenue for growth and market penetration.